Bioenergenix LLC

Nimbus Iris, Inc.

Tetra Discovery Partners, LLC

Nimbus Lakshmi, Inc.

Centaurus Therapeutics

The Upjohn Co.

Vettore, LLC

Pharmacia & Upjohn Company

Other

Nimbus Lakshimi, Inc.

Vincere Biosciences, Inc.

Donna Lee Romero

John Michael McCall

Jeremy Robert Greenwood

Craig E Masse

Geraldine C Harriman

Mee Shelley

Shaughnessy Robinson

Ronald Thure Wester

Mark E Gurney

Xuesheng Mo

Michael John Clare

Timothy J Hagen

Robert Campbell

Joel R Walker

Joshua Jahmil Kennedy-Smith

Lei Zhu

Markus Dahlgren

A Samuel Vellekoop

Matthew David Wessel

Robert C Kelly

John McKearn

Rosana Kapeller-Libermann

Richard Charles Thomas

Sayan Mondal

John R Palmer

Jeremy T Blitzer

Kenneth Mark Parnell

Paul A Aristoff

Leah Lynn Frye

Alan Franklin Corin

Karl Shawn Watts

Gordon L Bundy

Herman W Smith

Michael R Barbachyn

Arthur Glenn Romero

Peter Laurence Toogood

Michael G Johnson

Dennis Joseph McNamara

Paul D May

Alexander Ross Hurd

Toni-Jo Poel

Lisa Marie Thomasco

Margaret S Lee

Debra Ann Sherry

Robert F Campbell

J Craig Ruble

Paul Joseph Dobrowolski

John Mccall

Gordan L Bundy

Jeremy Blitzer

Andrew David Lee

Bahareh Behrouz

Glenn F Short, Iii

Richard Allen Nugent

James Craig Ruble

Edward Lawrence Fritzen, Jr

Gary E Martin

A G c/o Pfizer Global Research & Dev Romero

D A c/o Pfizer Global Research & Dev Sherry

P J c/o Pfizer Global Res & Dev Dobrowolski

P L c/o Pfizer Global Research & Dev Toogood

M R c/o Pfizer Global Res & Dev Barbachyn

L M c/o Pfizer Global Research & Dev Thomasco

D J c/o Pfizer Global Research & Dev Mcnamara

A R c/o Pfizer Global Res & Dev Hurd

Ronald T Wester

John Raymond Palmer

Dennis Joseph Mcnamara

Michael Robert Barbachyn

John Mckearn

Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Heterocyclic inhibitors of MCT4

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

Heteroaryl inhibitors of PDE4

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Inhibitors of dihydroceramide desaturase for treating disease

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

USP30 inhibitors and uses thereof

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Heterocyclic compounds for the inhibition of PASK

The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders. 

TYK2 inhibitors and uses thereof

Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:  Methods of inhibition MCT4 activity in a human or animal subject are also provided.

The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic compounds (e.g., compounds according to any of Formulas (I)-(III) or Compounds (1)-(65) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

Heterocyclic inhibitors of the sodium channel

Disclosed herein are new heterocyclic compounds and compositions having structural Formula (I) and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus. 

Provided herein are phosphodiesterase 4D (PDE4D) inhibitors, including methods of using the same. Also provided are methods of treating subjects suffering from conditions associated with aberrant PDE activity.

PDE4D inhibitors

Growing community of inventors

Chesterfield, MO, United States of America

Donna Lee Romero